More on AKTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $8.70 |
|
|||
| Open | $8.62 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $7.63 | ||||
| Day High | $9.54 | ||||
| Day Low | $8.08 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 52,713 | ||||
- Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
- Akari Therapeutics enters ADC research deal with Whitehawk Therapeutics
- Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
- Maxim Group Upgrades Akari Therapeutics (AKTX) to Buy
- Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board
- Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
- Akari Therapeutics closes $5.5M PIPE, raises $8.3M total in Q2 2026
- Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
- Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
- Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
Entities mentioned with AKTX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Dividend | View Related Stories »
- 13G | View Related Stories »
- Show More...
